Comparative in vitro activity of LY121019 and amphotericin B against clinical isolates ofCandida species
- 1 February 1988
- journal article
- research article
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 7 (1), 80-81
- https://doi.org/10.1007/bf01962183
Abstract
LY121019 and amphotericin B were equally active in vitro against most clinical isolates ofCandida albicans andCandida tropicalis. Higher concentrations of LY121019 were required for inhibition ofCandida glabrata. OtherCandida species were inhibited by amphotericin B but not by LY121019.This publication has 6 references indexed in Scilit:
- Fungemia in a Cancer Hospital: Changing Frequency, Earlier Onset, and Results of TherapyClinical Infectious Diseases, 1985
- In vitro and in vivo anti-Candida activity and toxicology of LY121019.The Journal of Antibiotics, 1984
- Antifungal Agents Useful in Therapy of Systemic Fungal InfectionsAnnual Review of Pharmacology and Toxicology, 1983
- Studies on the mechanism of antifungal action of aculeacin A.The Journal of Antibiotics, 1982
- Incidence of polyene-resistant yeasts recovered from clinical specimensAntimicrobial Agents and Chemotherapy, 1980
- Papulacandin B: an Inhibitor of Glucan Synthesis in Yeast SpheroplastsEuropean Journal of Biochemistry, 1979